Effects of growth hormone (GH) hypersecretion on somatostatin-(SRIH) and GH-releasing hormone (GHRH) were studied by in situ hybridization and receptor autoradiography in rats bearing a GH-secreting tumor. 6 and 18 wk after tumor induction, animals displayed a sharp increase in body weight and GH plasma levels; pituitary GH content was reduced by 47 and 55%, while that of prolactin and thyrotropin was unchanged. At 18 wk, hypothalamic GHRH and SRIH levels had fallen by 84 and 52%, respectively. In parallel, the density of GHRH mRNA per arcuate neuron was reduced by 52 and 50% at 6 and 18 wk, while SRIH mRNA levels increased by 71 and 83% in the periventricular nucleus (with no alteration in the hilus of the dentate gyrus). The numbers of GHRH-and SRIH-synthetizing neurons in the hypothalamus were not altered in GH-hypersecreting rats. Resection of the tumor restored hypothalamic GHRH and SRIH mRNAs to control levels. GH hypersecretion did not modify 1211-SRIH binding sites on GHRH neurons. Thus, chronic GH hypersecretion affects the expression of the genes encoding for GHRH and SRIH. The effect is long lasting, not desensitizable and reversible. (J.
Introduction
Growth hormone (GH)' secretion by the anterior pituitary is regulated by a complex interplay between two hypothalamic hormones with opposite effects: GH-releasing hormone (GHRH) and somatotropin-releasing inhibitory hormone (SRIH), also named somatostatin ( 1 ). GHRH-containing proPart of this work was presented in abstract form at the XXeme Colloque de la Soci&W de Neuroendocrinogie Experimentale, Geneva, Swit-jections to the median eminence originate almost exclusively from neurons of the arcuate nucleus, while SRIH-containing terminals arise mainly from the hypothalamic periventricular nucleus.
There is considerable evidence that GH regulates its own rhythmic secretion through a negative feedback mechanism (2) . Pituitary GH content and release are reduced in rats treated with exogenous GH or bearing ectopic somatotropic tumors (3) (4) (5) . The mechanisms of GH feedback control have been investigated by assessing the hypothalamic content or release of GHRH and SRIH, and by measuring the corresponding hypothalamic mRNA levels. GH deprivation by hypophysectomy leads to a reduction in the hypothalamic content and release of SRIH (6) (7) (8) (9) (10) , but GHRH content is also reduced in the same model (10) (11) (12) (13) (14) . This has been attributed to an increase in the hypothalamic release of GHRH, although this phenomenon has not been consistently observed (12, 14) . These apparent discrepancies underline the difficulty in interpreting changes in peptide content, which reflect the rate of both synthesis and release. With regard to peptide synthesis, GHRH mRNA levels are strongly increased after hypophysectomy ( 15, 16) , while conflicting data have been obtained for SRIH mRNA, the level of which was either reduced (16) or unaltered ( 13, 15) . These data do not permit to conclude on the specific effect of GH since hypophysectomy elicits a multiendocrine deficit and treatment of hypophysectomised rats with tetraiodothyronine, corticosterone, and testosterone is sufficient to reverse the increase in GHRH mRNA levels, even in the absence of GH ( 15) . In addition, exogenous GH treatment in hypophysectomised rats either failed ( 15) or only partially restored SRIH and GHRH hypothalamic content (12) (13) (14) . Earlier studies using short-term administration of GH or implantation ofGH/prolactin-secreting tumors in normal rats concluded to a feedback effect of GH (6, 9, 14, 16) , but more recent ones either failed to demonstrate any effect on SRIH content ( 17) or showed an effect restricted to male animals ( 18) .
In this study, we used a rat model of GH hypersecretion induced by subcutaneous injection of GH-secreting cells (GC) that rapidly grow as solid, functional tumors ( 19) . We studied the long-term feedback effects of GH hypersecretion on SRIH and GHRH at the hypothalamic level, and the reversibility of the observed changes after tumor resection. Hypothalamic SRIH and GHRH mRNA levels were determined at 6 and 18 wk by in situ hybridization in female rats bearing ectopic GHproducing tumors. As SRIH-specific receptors have recently been located on GHRH neurons (20) (21) (22) , we also used quantitative light microscopic autoradiography (23) In situ hybridization was carried out as described elsewhere (25) . Briefly, 45 -base oligoprobes (bases 31-75 of rat GHRH cDNA [33] and bases 96-111 of rat SRIH cDNA [34] GHRH, respectively. Autoradiograms were developed in Dektol (Kodak, Marnes la Vallee, France), stained with cresyl violet, and coverslipped. The specificity of labelling has been reported elsewhere (25, 
35). '25I-SRIH autoradiography
Monoiodo Tyro DTrp8 SRIH 14 (Peninsula) was labelled with chloramine T '251I-SRIH (780 Ci/mM). The labeled tracer was purified on a carboxymethyl cellulose column (CM52; Whatman Inc, Clifton, NJ) by stepwise elution with 2-200 mM ammonium acetate at pH 4.6.
'251-SRIH binding experiments were performed on series of adjacent coronal sections as previously described (20) . Sections were preincubated for 15 min at room temperature in 0.05 M Tris-HCl buffer (pH 7.4) containing 0.25 M sucrose and 0.2% BSA. They were then incubated for 45 min at room temperature in the same medium supplemented with '251-SRIH, MgCl2 5 x 10-3 M, and bacitracin 5 X IO5 M.
To determine nonspecific binding, sections adjacent to those used for total binding were incubated in the presence of 1 gM nonradioactive SRIH 14; specific binding was calculated as the difference between total and nonspecific binding. After incubation, sections were rinsed in two consecutive ice-cold baths of supplemented Tris buffer (5 min/bath) and immediately fixed by immersion in 4% glutaraldehyde in 0.05 M phosphate buffer for 30 min at 4VC (9) . This procedure irreversibly cross-links > 90% of 1251I-SRIH molecules to tissue proteins (36) . After fixation, sections were dehydrated in a graded ethanol series, defatted in xylene, rehydrated, and coated by dipping in Ilford K5 emulsion. After 4-6 wk exposure, the autoradiograms were developed and stained as for in situ hybridization.
Image analysis and quantification '25I-SRIHautoradiography. Sections were examined with a Leitz orthoplan microscope coupled to a computerized image analysis system (RAG 200; Biocom, Les Ulis, France). Cells were located with bright field illumination and 1251I-SRIH labeling was quantified under dark field illumination (23). Optical density was converted into radioactivity units (dpm/pixel) with reference to standards prepared from brain pastes with known concentrations of '25I-SRIH. A series of standards was treated in parallel with the experimental sections in each experiment. Pericellular grains were quantified in the arcuate nucleus by tracing a circle of uniform diameter on the highly labeled perikarya. A minimum of 10 cell bodies were measured on each side of the third ventricle. 1251I-SRIH binding was also quantified on the same sections at the level of the dentate gyrus of the hippocampus, which showed homogenous labeling. A minimum of 10 sections were analyzed for each animal. Specific binding amounted to 70% oftotal binding in the dentate gyrus of the hippocampus, and 50% in the arcuate nucleus.
In situ GHRH and SRIH hybridization. Grain density was quantified using epifluorescence illumination and the Histo program (Biocom), which gives densitometric integration of the number of grains per cell. Labeled cells were identified by cresyl violet staining of the nucleus, associated with a cluster ofsilver grains. Clusters were counted ifthe number ofgrains was above the background level on each section. The number of grains was quantified by tracing a circle of uniform diameter on the perikarya. For both regions and probes, a minimum of six sections were analyzed for each animal.
Statistical analysis
Data are expressed as means±SEM. Groups were compared using oneway ANOVA and a posteriori using Fisher's test to compare tumorbearing rats to controls, tumor-bearing to tumor-resected rats, and tumor-resected rats to controls.
Results

Effects oftumor growth on rat body weight and plasma GH levels
The main characteristics of the tumor-bearing and control rats used in the neuroanatomical studies are shown in Table I . Body weight increased in tumor-bearing rats 6 and 18 wk after GC cell injection (53 and 116%, respectively, compared to the corresponding controls). This was accompanied by a very strong increase in GH plasma levels. Body weight fell significantly after resection ofthe tumor, but remained higher than in age-matched controls. Plasma GH levels returned to control values. In the group of rats dissected for hypothalamic peptide measurements, 18 wk after GC cell injection, tumors weighed 38.4±4.3 g. Body weight (tumor-bearing rats [n = 5]: 442±22 g; controls [n = 5]: 217+6, P < 0.01 ) and GH plasma levels (tumor-bearing rats: 6,953±1,993 Ag/liter; controls: 7±1, P < 0.01 ) increases were equivalent to those described in Table I . Hormone content in the pituitary Pituitary contents of GH, prolactin, and TSH were assessed in 6-wk tumor-bearing rats (n = 5) and controls (n = 5). The weight of the pituitary was similar in both groups ( 10.1 ± 1 mg and 11.8±0.4 mg in control and tumor-bearing rats, respectively Fig. 3 and 4) . After tumorectomy, SRIH mRNA labeling was similar to control values, and fell by 56% relative to the tumor-bearing rats. In this nucleus, the numbers of SRIH-hybridizing cells were not significantly different between the controls and the experimental animals (at 6 wk, controls: 40±6 cells/hemisection, tumor-bearing rats: 46±4, NS; at 18 wk, controls: 38±5, tumor-bearing rats: 49±4, and tumor-resected rats: 46±6, NS). SRIH mRNA levels were also measured in the dentate gyrus to check the regional specificity of the changes in the hypothalamus. No difference was found between the various experimental groups: The number of grains per cell was 30±5 in the controls and 34±3 in the tumor-bearing rats at 6 wk; the values were, respectively, 23±3 and 24±4 at 18 wk; the value in the tumorectomized animals was 18±3. I251-SRIH binding. Within the arcuate nucleus, no difference was observed in pericellular specific 125I-SRIH binding in the tumor-bearing rats at 6 or 18 wk relative to their respective controls and to values after tumorectomy (Fig. 5) . Representative sections are shown in Fig. 6 . Similarly, no differences were observed within the dentate gyrus in the various treatment groups compared to their controls: 6 wk after cell injection, specific '25I-SRIH binding was 2,326±229 dpm in the controls and 2,721±609 dpm in the tumor-bearing rats. At 18 wk, values were 2,833±239 and 2,506±367 dpm, respectively, and 2,572±408 dpm after tumorectomy.
Discussion
The data reported herein point to persistent effects of GH hypersecretion on the GHRH/SRIH hypothalamic network during chronic GH hypersecretion in the rat.
We used GC tumor-bearing rats to study the specific effects of chronic GH hypersecretion on the regulation of the growth hormone axis. Other cell lines used to induce ectopic somatotropic tumors (4, 18, 37, 38) usually secrete both GH and prolactin in vitro, and, occasionally, in vivo. In contrast, GC cells do not secrete prolactin in vitro (39) and prolactin plasma levels are not increased in GC tumor-bearing rats ( 19) .
There was a very strong increase in GH plasma levels and body weight 6 wk after GC cell injection, with a further increase at 18 wk. Removal of the tumor led to a fall in GH plasma levels to the normal range. Pituitary GH content was reduced by 54-64% in the tumor-bearing animals, supporting the negative feedback effect ofchronically increased circulating GH levels. In contrast, GH hypersecretion did not affect pituitary prolactin or TSH content.
Hypothalamic GHRH content was reduced in 18 wk tumor-bearing rats, suggesting a long term negative feedback effect ofGH plasma levels, but hypothalamic SRIH content also fell in the same animals. Studies on the effect ofGH on GHRH and SRIH hypothalamic contents yielded conflicting results. In intact rats, GH administration for 1 or 2 wk led to either a moderate decrease ( 18) or no apparent change ofGHRH contents ( 17) , while SRIH content was not modified. Hypophysectomy resulted in a considerable decrease in SRIH hypothalamic levels (6, 7, 9, 17) but also in GHRH content (1 1 3,  17) , a result that mirrors our observations of the effect of chronic GH hypersecretion. Also, in hypophysectomized animals, treatment with GH either did not modify ( 17) or only partially restored GHRH concentrations ( 12, 13, 17) and had only minimal effects on SRIH hypothalamic contents (6, 7). Moreover, the effects of GH appeared to be sex dependent, being more pronounced in males than in females, as well as time dependent ( 18) . Indeed no changes in GHRH and SRIH contents were observed 2 wk after implantation of the GH/ PRL-secreting MtTW15 tumor. By contrast, at 4 wk, a decrease in GHRH content was noticed, but of a smaller extent ( 18%) than in our study (84%), and no effect was apparent on SRIH content ( 18) . It is therefore tempting to speculate that the differences observed in the effects of high GH in these various studies may be caused by the different time course of the experiments, as well as a sex difference. At the opposite, in conditions of life-long GH deficiency, such as in the Lewis Dw/Dw dwarf rat, GHRH contents are increased 1.45-fold and SRIH contents are decreased by 74% as compared to con- trols (40) . However, in another dwarf rat strain, the SDRs, the number ofGHRH-containing cells are doubled as compared to controls, while SRIH-containing cells are only minimally affected, and median eminence terminals containing both peptides seems unchanged (41, 42) . It is therefore difficult to conclude about GH feedback actions only from the measurement of peptide contents, since the latter reflects variations in the rates of both synthesis and release. We thus measured peptide mRNA levels using a quantitative in situ hybridization method. GHRH mRNA levels in the arcuate nucleus were decreased in tumor-bearing rats. This observation is in keeping with the changes previously reported in normal rats after hypophysectomy and GH replacement ( 13, 15 ( 16) but not by others ( 13, 15) . These differing results might be explained by the use of Northern blot analysis ( 13, 15) compared to in situ hybridization ( 16) . Indeed, SRIH-synthesizing cells are widely distriba.
-1600. The finding that in presence of high GH levels, SRIH mRNA levels are increased in parallel with a decrease in GHRH mRNA levels, is consistent with several lines of evidence indicating that SRIH could inhibit GHRH synthesis within the arcuate nucleus (see reference 20 for review) through specific receptors located on GHRH neurons (23, 25) . Recently, it has been shown that SRIH inhibits GHRH release in vitro on rat hypothalamic explants (45) and in vivo in conscious sheep (46) . Interestingly, high GH levels also increase hypothalamic SRIH release (6, 9) . We thus investigated whether SRIH receptors located on GHRH neurons were also affected by GH hypersecretion. The fact that '25I-SRIH specific binding on arcuate nucleus perikarya was not altered might indicate that SRIH receptors on GHRH neurons are not desensitized in the presence of high SRIH levels resulting from the stimulation ofperiventricular somatostatinergic neurons stimulated by increased GH secretion. Alternatively, SRIH fibers innervating GHRH arcuate neurons might originate from another source than the GH-regulated periventricular hypothalamic system, and this could also explain the lack of modification in '25I-SRIH specific binding on arcuate nucleus perikarya. At any rate, these observations suggest that the ability of SRIH to inhibit GHRH arcuate neurons by acting on specific receptors is maintained during GH hypersecretion. The decrease in GHRH mRNA levels might thus be mediated by direct SRIH inhibition within the arcuate nucleus.
The mechanisms of GH feedback control of SRIH and GHRH synthesis are still unknown, although a direct effect of GH at the hypothalamic level through a short-loop mechanism 1788 Bertherat et al. has been suggested. In the rat, central administration ofGH led to a decrease in GH plasma levels (3). In the same respect, transgenic mice that selectively express the GH gene in the central nervous system exhibit low plasma levels of GH (47) . GH receptor mRNAs have been evidenced by in situ hybridization in the arcuate and periventricular nucleus with a distribution similar to that of GHRH and SRIH neurons (48) . However, the presence of GH receptor mRNAs is not always associated with that of functional GH binding sites (49) . Alternatively, GH feedback could be explained by an indirect pathway through a long-loop mechanism involving intermediate factors such as insulin-like growth factors( 50), since binding sites for insulin-like growth factors 1 and 2 have been described in the hypothalamus (51) . However, it has recently been shown that short-term GH hypersecretion exerts negative feedback without modifying IGF-I plasma levels (52) . On the other hand, in the GH-deficient Lewis Dw/Dw rat, GH regulates GHRH mRNA levels independently of IGF-I, while SRIH mRNA modulation is dependent on the latter only (53) . Thus, the respective roles ofGH and insulin-like growth factors in these feedback mechanisms remain to be clarified.
In conclusion, GH feedback controls hypothalamic peptide synthesis through an inhibition ofGHRH mRNA and a stimulation ofSRIH mRNA, and persists during chronic exposure to high levels ofgrowth hormone in the rat. Despite the long-term GH hypersecretion, the changes observed in SRIH and GHRH mRNA levels are reversible after normalization of GH plasma levels. '251-SRIH specific binding sites are not altered in the arcuate nucleus, suggesting that SRIH may still act at this level as an inhibitory factor in the complex interplay between the two neurohormones.
